TABLE IV.
Comparison of the Results of the Current Study and a Previous Large U.S. Prospective Study Conducted by the NHLBI [2], n (%)
| NHLBI study | Current study | |
|---|---|---|
| Study Period | 1975–1979 | 2006–2012 |
| Number of Patients Enrolled | 1306 | 824 |
| Number of New Inhibitors | 31 (2.4%) | 23 (2.8%) |
| Severity | ||
| Severe | 21 (68) | 15 (65) |
| Moderate or mild | 10 (32) | 8 (35) |
| Age | ||
| Median | 16 | 5a |
| Range | 2–62 | 1–61 |
| Exposure days | ||
| 0–20 | 3 (10) | 10 (43)a |
| 21–100 | 14 (45) | 6 (26) |
| 101–150 | 4 (13) | 1 (4) |
| >150 | 10 (32) | 6 (26) |
| Clinical indicationb | 11 (35) | 9 (39) |
| Repeat specimen positivec | 24/31 (77) | 14/16 (88) |
a
Significantly different at P <0.05.
b
Detected when tested due to clinical suspicion of an inhibitor rather than at study screening.
c
Of those repeated.